Bildkälla: Stockfoto

Index Pharma Q2’21: CONCLUDE About to Commence - Redeye

Redeye leaves its view on InDex Pharmaceuticals following the announcement of its Q2 report. The company’s pivotal phase III study will commence shortly, and we see an attractive entry-level into the share.

Redeye leaves its view on InDex Pharmaceuticals following the announcement of its Q2 report. The company’s pivotal phase III study will commence shortly, and we see an attractive entry-level into the share.
Börsvärldens nyhetsbrev
ANNONSER